Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.
Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.
Ironwood Pharmaceuticals reported proposed sales of Class A Common Stock on a Form 144, listing multiple blocks of shares tied to restricted stock unit awards. The notice lists amounts including 27,780; 8,905; 8,485; and 6,825 shares associated with RSU awards dated 02/24/2022, 02/23/2023, 02/22/2024, and 01/27/2025.
The entries state each lot is a "Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan" (or amended plan) and are shown with vesting requirements. The filing is a routine Rule 144 notice of proposed resale activity and does not disclose sale prices, purchasers, or final transaction timing.
Ironwood Pharmaceuticals reported a proposed sale of Class A common stock under a Form 144 notice, identifying shares derived from multiple restricted stock unit awards. The filing lists awards dated 02/24/2022 (4,244 shares), 04/01/2022 (7,500), 02/23/2023 (8,905), 02/22/2024 (6,825), and 01/27/2025 (27,778).
Ironwood Pharmaceuticals, Inc. submitted a Form 144 notice reporting proposed sales of Class A Common Stock tied to previously granted restricted stock unit awards. The excerpt lists example lots of 20,362, 17,467, 13,606, and 33,334 shares associated with award grant dates from 03/02/2022 through 02/10/2025.
Ironwood Pharmaceuticals, Inc. submitted a Form 144 proposing resale of Class A common stock derived from restricted stock unit awards. The filing lists grant-dated lots of shares awarded on 03/02/2022, 03/08/2023, 02/12/2024, and 02/10/2025.
The excerpt includes per-lot quantities, including 16,969 and 16,375 shares as examples; these lots are described as restricted stock unit awards under the company's equity incentive plan. Timing and aggregate resale proceeds are not provided in the excerpt.
Ironwood Pharmaceuticals reported proposed sales of Class A common stock via a Form 144 tied to restricted stock unit awards, including awards of 62,218 (03/08/2022), 80,198 (03/08/2023), 88,292 (03/05/2024) and 180,000 (05/20/2025) shares.
Each listed award was granted under the Issuer's 2019 Equity Incentive Plan or its amended and restated 2019 Equity Incentive Plan. The filing lists the securities and grant dates associated with the proposed sales.
Ironwood Pharmaceuticals reports a 9.85% beneficial stake held by Armistice Capital and Steven Boyd. The filing shows 16,025,000 shares of Class A common stock as beneficially owned as of 12/31/2025, with 16,025,000 shares of shared voting power and shared dispositive power.
The statement filed jointly and signed 02/17/2026 attributes ownership to Armistice Capital as investment manager of Armistice Capital Master Fund Ltd.; the Master Fund is identified as the direct holder.
Ironwood Pharmaceuticals officer Ronald Silver reported a planned stock sale. On January 5, 2026, he sold 35,416 shares of Ironwood Class A Common Stock at $4.60 per share in a transaction coded as a sale. The filing states this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Silver, which is designed to allow insiders to sell shares according to a set schedule. After this transaction, he beneficially owned 276,809 shares of Ironwood stock, held directly. A footnote explains that the 35,416 shares sold had been acquired under Ironwood’s employee stock purchase plan on December 31, 2025.
Ironwood Pharmaceuticals insider activity: A reporting person associated with Ironwood Pharmaceuticals received an award of 4,178 shares of Class A common stock on 12/15/2025 at a price of $0 per share. The filing states this grant was issued under the company’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
After this transaction, the reporting person directly beneficially owns 251,858 Class A shares and indirectly beneficially owns 15,919,435 Class A shares through Sarissa Capital Management LP and related funds, reflecting both personal and fund-related positions in IRONWOOD PHARMACEUTICALS INC (IRWD).
Ironwood Pharmaceuticals reported that the U.S. Department of Health and Human Services has set the Medicare “Maximum Fair Price” for LINZESS (linaclotide) at $136 for a 30-day equivalent supply. This Maximum Fair Price will become the new Medicare net price starting January 1, 2027 under the Inflation Reduction Act of 2022.
The company states that this revised price for LINZESS is in line with its expectations, indicating the decision aligns with its planning around the product’s U.S. Medicare pricing.
Ironwood Pharmaceuticals Inc. (IRWD) reported an insider transaction by its Chief Commercial Officer. On 11/17/2025, the officer sold 6,016 shares of Class A common stock at $3.32 per share. According to the disclosure, this sale was made automatically to cover tax withholding obligations arising from the vesting of restricted stock units and was not a discretionary trade. After this transaction, the officer beneficially owned 235,264 shares of Ironwood common stock.